SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Authors
Keywords
-
Journal
HEART FAILURE REVIEWS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-13
DOI
10.1007/s10741-021-10096-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
- (2021) Shigenori Hiruma et al. Cardiovascular Diabetology
- Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer
- (2020) Sharanya Sivanand et al. CANCER CELL
- Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization
- (2020) Yoshiyuki Hattori HEART FAILURE REVIEWS
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- (2020) So Ra Kim et al. Nature Communications
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
- (2020) Antonios Douros et al. ANNALS OF INTERNAL MEDICINE
- The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
- (2020) Emily A. Day et al. BIOCHEMICAL JOURNAL
- Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
- (2020) Alice M. Jackson et al. CIRCULATION
- Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
- (2020) Ele Ferrannini et al. DIABETES CARE
- Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
- (2020) Julio M. Martinez-Moreno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- (2020) Martin R. Cowie et al. Nature Reviews Cardiology
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
- (2020) Kieran F. Docherty et al. CIRCULATION
- Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
- (2020) Milton Packer et al. CIRCULATION
- Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
- (2020) Matteo Serenelli et al. EUROPEAN HEART JOURNAL
- Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
- (2020) Adriana Marton et al. Nature Reviews Nephrology
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
- (2020) Kristian B Filion et al. BMJ-British Medical Journal
- Understanding the Mechanistic Benefit of Heart Failure Drugs Matters
- (2020) James L. Januzzi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors may offer benefit beyond diabetes
- (2020) Amy Kang et al. Nature Reviews Nephrology
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
- (2020) Nikolaus Marx et al. Lancet Diabetes & Endocrinology
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice
- (2020) Muthiah Vaduganathan et al. JAMA Cardiology
- Branched-chain amino acids in disease
- (2019) Phillip J. White et al. SCIENCE
- Diabetic cardiomyopathy: factual or factoid?
- (2019) Thiago Quinaglia et al. Revista da Associacao Medica Brasileira
- Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus
- (2019) Yoko Koike et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- (2019) Damilola D. Adingupu et al. Cardiovascular Diabetology
- Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
- (2019) Hana E. Baker et al. BASIC RESEARCH IN CARDIOLOGY
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiac ischemia–reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity
- (2019) Akira Yoshii et al. Cardiovascular Diabetology
- Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
- (2019) Álvaro García-Ropero et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
- (2019) Subodh Verma AMERICAN JOURNAL OF CARDIOLOGY
- BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes
- (2019) Anna R. Hemnes et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
- (2019) Yei-Tsung Chen et al. Cells
- Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
- (2018) Franco Cosmi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
- (2018) Abdullah Kaplan et al. HEART FAILURE REVIEWS
- Cardiac metabolism — A promising therapeutic target for heart failure
- (2018) Hannah Noordali et al. PHARMACOLOGY & THERAPEUTICS
- Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism
- (2018) Mark Y. Jeong et al. Science Translational Medicine
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Diabetes and branched-chain amino acids: What is the link?
- (2018) Zachary Bloomgarden Journal of Diabetes
- Glucagon Levels during Short-term SGLT2 Inhibition are Largely Regulated by Glucose Changes in Type 2 Diabetes Patients
- (2018) Per Lundkvist et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts
- (2018) Andreas L. Birkenfeld et al. PHARMACOLOGY & THERAPEUTICS
- A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
- (2018) Aysegul Durak et al. Cardiovascular Diabetology
- Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice
- (2018) Desiree Abdurrachim et al. CARDIOVASCULAR RESEARCH
- Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.
- (2018) Hiroto Oshima et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism
- (2018) Hideya Shintani et al. Nutrients
- The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
- (2017) Yusuke Nakatsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
- (2017) Vance B. Matthews et al. JOURNAL OF HYPERTENSION
- The diabetic heart utilizes ketone bodies as an energy source
- (2017) Yuji Mizuno et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis
- (2017) Hiroyuki Iuchi et al. Scientific Reports
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients
- (2017) Núria Farré et al. PLoS One
- Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure?
- (2016) Stephen C. Kolwicz et al. CIRCULATION
- Failing Heart and Starving Brain
- (2016) Heinrich Taegtmeyer CIRCULATION
- The Failing Heart Relies on Ketone Bodies as a Fuel
- (2016) Gregory Aubert et al. CIRCULATION
- Catabolic Defect of Branched-Chain Amino Acids Promotes Heart FailureCLINICAL PERSPECTIVE
- (2016) Haipeng Sun et al. CIRCULATION
- Insulin Signaling and Heart Failure
- (2016) Christian Riehle et al. CIRCULATION RESEARCH
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart
- (2016) Anja Karlstaedt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
- (2016) Sanjay Kalra et al. Diabetes Therapy
- The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
- (2016) Sanjay Kalra et al. Diabetes Therapy
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Estimates of Global and Regional Premature Cardiovascular Mortality in 2025
- (2015) Gregory A. Roth et al. CIRCULATION
- Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined13C Hyperpolarized Magnetic Resonance and Echocardiography Study
- (2015) Lydia M. Le Page et al. DIABETES
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure
- (2015) Kayla Riggs et al. Metabolic Syndrome and Related Disorders
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
- (2015) Beshay N. Zordoky et al. PLoS One
- Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling
- (2014) Osama Abo Alrob et al. CARDIOVASCULAR RESEARCH
- Lowering Body Weight in Obese Mice With Diastolic Heart Failure Improves Cardiac Insulin Sensitivity and Function: Implications for the Obesity Paradox
- (2014) Sowndramalingam Sankaralingam et al. DIABETES
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- The Global Health and Economic Burden of Hospitalizations for Heart Failure
- (2014) Andrew P. Ambrosy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4
- (2013) Jun Mori et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Cardiac Insulin-Resistance and Decreased Mitochondrial Energy Production Precede the Development of Systolic Heart Failure After Pressure-Overload Hypertrophy
- (2013) Liyan Zhang et al. Circulation-Heart Failure
- p53-Induced Adipose Tissue Inflammation Is Critically Involved in the Development of Insulin Resistance in Heart Failure
- (2012) Ippei Shimizu et al. Cell Metabolism
- Lipid Metabolism and Toxicity in the Heart
- (2012) Ira J. Goldberg et al. Cell Metabolism
- Glucose, Obesity, Metabolic Syndrome, and Diabetes
- (2010) Tamara B. Horwich et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More